< Back to all Team Members

Todd Tillmanns, MD, FACOG

Gynecologic Oncologist
Specialty Area
Cancer Type
Team Role
Primary Location
7945 Wolf River Boulevard
Germantown, TN 38138
Phone: 901.683.0055
Secondary Location(s)
1588 Union Avenue
Memphis, TN 38104
Phone: 901.683.0055
405 East Jackson Avenue
Jonesboro, AR 72401
Phone: 870.207.8177
7668 Airways Boulevard
Southaven, MS 38671
Phone: 662.349.9556

Todd Tillmanns, MD, FACOG, is a noted Gynecologic Oncologist recognized by his patients and colleagues for his uncompromising standards of care, offering the very latest and best minimally invasive options for surgery and chemotherapeutic strategies. Dr. Tillmanns treats women’s cancers and is especially interested in minimally invasive and robotic surgery approaches, as well as the latest treatment for ovarian and endometrial cancer.

Titles and Roles

  • Board Certified Gynecologic Oncologist, West Cancer Center
  • Professor, Division of Gynecologic Oncology, University of Tennessee Health Science Center
  • Director of the Pelvic Surgery Fellowship, West Cancer Center
  • President and Founding member, Memphis Robotic and Minimally Invasive Surgery Society
  • Head of Gynecologic Malignancies Tumor Board
  • Executive Cancer Council, Voting Member
  • Executive Committee, West Cancer Center
  • Cancer Center Committee
  • West Cancer Center Research Committee

Areas of Expertise

  • Women’s Cancers
  • Minimally Invasive and Robotic Surgery

Biography

Dr. Tillmanns sees patients at West Cancer Center locations in East Memphis, Midtown, Southaven and Jonesboro. Both patients and professional colleagues appreciate Dr. Tillmanns’ uncompromising standards of care. He is known for being very attentive and attuned to his patients’ needs.

Dr. Tillmanns is the President of the Memphis Robotic and Minimally Invasive Surgery Society in which he and Dr. Mark Reed, as well as numerous other local surgeons, are all founding members. The Memphis Robotic and Minimally Invasive Surgery Society is a collaborative effort of surgeons in the greater Memphis area committed to improving minimally invasive surgery to patients in this region and providing the highest level of robotic surgery in all specialties.

When Dr. Tillmanns is not caring for patients, he and his wife and two daughters, enjoy an active outdoor lifestyle consisting of mountain and road biking, water and snow skiing, fly fishing, hunting, and tennis. He is also a lifelong soccer player. More sedentary pursuits also capture his attention. Dr. Tillmanns is a published poet who also cooks, bakes, paints, draws, carves wood, creates photographic collages, and grows orchids, berries and is a winemaker.

Education and Training

Dr. Tillmanns completed his Fellowship in Gynecologic Oncology at the University of Oklahoma Health Science Center, Department of OBGYN, Section of Oncology, in Oklahoma City, where he also served as a Clinical Instructor. For his Internship and Residency in Obstetrics and Gynecology, he sought training at the Medical College of Wisconsin in Milwaukee. Dr. Tillmanns graduated with clinical honors from Medical School at Creighton University, Omaha, Nebraska. He majored in biology with honors and earned a Bachelor of Arts Degree from the University of San Diego.

Awards

Dr. Tillmanns recent honors and awards include:

  • Executive Cancer Council-Voting Member
  • Executive Committee West Cancer Center
  • Cancer Center Committee
  • Oncologist of the Year, Tennessee Research Project, 2009
  • Golden Apple Teaching Award, University of TN Health Science Center  2006, 2007, 2008, 2009, and 2012.

Research

Dr. Tillmanns’ is actively involved in research at the West Cancer Center. Recent research interests include:

  • Scopolamine Patch for postoperative nausea and vomiting in Robotic Gynecologic Surgery
  • Vaginal Cuff Closure in Robotic Hysterectomy: A Randomized Controlled Trial of Barbed Suture
  • Principal Investigator – Novartis CTKI258A2211: A phase II open label nonrandomized multicenter study to evaluate the efficacy of oral TKI258 as second line therapy in patients with either FGFR2 mutated or wild type advanced endometrial cancer.
  • Neoadjuvant Chemotherapy for Stage III/IV Endometrial Cancer.
  • Robotics Consortium to Evaluate Pre/Post Operative Outcomes: A Retrospective Study.

Publications

To view Dr. Tillmanns’ most recent publications, click here.